Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MOVIPREP · 1 trial · 1 indication
Bowel cleansing was assessed by a blinded endoscopist through visual evaluation of 5 colon segments and scored using the Harefield Cleansing Scale (HCS): A = success, all segments clean/scored 4 or 3; B = success, ≥1 segment with liquid/semi-solid amounts of stool, fully removable, ≥1 segment scored 2; C = failure, ≥1 segment with semi-solid or solid amounts of stool, at least 1 segment scored 1; and D = failure, ≥ 1 segment with irremovable, heavy, hard stools, ≥ 1 segment scored 0. Segmental evaluation of colon cleansing scores is as follows: 4: Colon empty and clean, no remaining stool or liquid. 3: Presence of clear liquid in the gut which can be removed by suction. 2: Brown liquid or semisolid remaining amounts of stool, fully removable. 1: Semisolid amounts of stool, only partially removable, difficult to make colonoscopy; 0: Irremovable, heavy, hard stools, colonoscopy impossible. Success of cleansing was defined as Grades of bowel cleansing А and В.
| Arm | Type | Description |
|---|---|---|
| MOVIPREP (Morning-only dose) | EXPERIMENTAL | MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy. |
| MOVIPREP (Split-dose) | OTHER | MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy. |
| Name | Type | Description |
|---|---|---|
| MOVIPREP | DRUG | MOVIPREP solution |
Inclusion Criteria: * male or female ≥18 years and ≤ 85 years * colonoscopy procedure indicated * willing to stay in the outpatient clinical site for colonoscopy and questionnaire completion * willing and able to undergo study-related procedures * informed consent signed by a patient for participat...
MOVIPREP is used for bowel preparation prior to endoscopic, radiological and other examinations, as well as surgical procedures that require an empty bowel. It is a small molecule gastrointestinal product being developed by Takeda Pharmaceutical Company Limited.
MOVIPREP is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The product is intended for bowel preparation before examinations and surgical procedures that require an empty bowel.
MOVIPREP is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 3 trial has been completed as part of its clinical development program.
MOVIPREP has one completed Phase 3 clinical trial, registered as NCT01732692. The study evaluated the efficacy, safety and tolerance of experimental morning-only MOVIPREP bowel preparation compared with split-dose with nocturnal pause MOVIPREP bowel preparation. The trial enrolled 140 participants in Kazakhstan and Russia.
MOVIPREP is the name used for this bowel preparation product. No alternative names have been reported for this drug in the available clinical trial information.